Our Portfolio

Calimmune was acquired by CSL Behring in 2022, resulting in a high multiple return for Desert Angels members and 3 Desert Angels Sidecar funds.

Calimmune assembled a world-class team with a demonstrated track record in HIV gene therapy, clinical development, and commercialization. Key members include Drs. Baltimore and Chen, Dr. Kayyem (Founder, CMS acquired by Motorola for $280 Mil.), and Louis Breton (Founder, CellzDirect acquired by Invitrogen for $58 Mil.). Dr. Symonds (CSO), while at J&J, led the largest Phase II HIV cell-delivered gene therapy clinical trial conducted to date.